Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

NCT02937844 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

BIOLOGICAL: Anti-PD-L1 CSR T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Beijing Sanbo Brain Hospital

Collaborators

[object Object]